584 related articles for article (PubMed ID: 35262371)
1. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
[TBL] [Abstract][Full Text] [Related]
2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
3. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
4. Type III and Not Type I Interferons Efficiently Prevent the Spread of Rotavirus in Human Intestinal Epithelial Cells.
Doldan P; Dai J; Metz-Zumaran C; Patton JT; Stanifer ML; Boulant S
J Virol; 2022 Sep; 96(17):e0070622. PubMed ID: 36000839
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of SARS-CoV-2 by type I and type III interferons.
Felgenhauer U; Schoen A; Gad HH; Hartmann R; Schaubmar AR; Failing K; Drosten C; Weber F
J Biol Chem; 2020 Oct; 295(41):13958-13964. PubMed ID: 32587093
[TBL] [Abstract][Full Text] [Related]
6. USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING.
Karlowitz R; Stanifer ML; Roedig J; Andrieux G; Bojkova D; Bechtel M; Smith S; Kowald L; Schubert R; Boerries M; Cinatl J; Boulant S; van Wijk SJL
Cell Death Dis; 2022 Aug; 13(8):684. PubMed ID: 35933402
[TBL] [Abstract][Full Text] [Related]
7. Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons.
Jafarzadeh A; Nemati M; Saha B; Bansode YD; Jafarzadeh S
Viral Immunol; 2021 Jun; 34(5):307-320. PubMed ID: 33147113
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
[TBL] [Abstract][Full Text] [Related]
9. Pseudorabies virus-induced expression and antiviral activity of type I or type III interferon depend on the type of infected epithelial cell.
Yin Y; Ma J; Van Waesberghe C; Devriendt B; Favoreel HW
Front Immunol; 2022; 13():1016982. PubMed ID: 36405751
[TBL] [Abstract][Full Text] [Related]
10. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
Park A; Iwasaki A
Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
[TBL] [Abstract][Full Text] [Related]
11. Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection.
Sohn SY; Hearing J; Mugavero J; Kirillov V; Gorbunova E; Helminiak L; Mishra S; Mackow E; Hearing P; Reich NC; Kim HK
mBio; 2021 Dec; 12(6):e0275621. PubMed ID: 34724828
[TBL] [Abstract][Full Text] [Related]
12. Type I and III interferons are good markers to monitor COVID-19 pathophysiology.
Darif D; Ejghal R; Desterke C; Outlioua A; Hammi I; Lemrani M; Hilali F; Guessous F; Zaid Y; Akarid K
Cytokine; 2023 May; 165():156172. PubMed ID: 36924609
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
[TBL] [Abstract][Full Text] [Related]
14. Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2.
Hatton CF; Botting RA; Dueñas ME; Haq IJ; Verdon B; Thompson BJ; Spegarova JS; Gothe F; Stephenson E; Gardner AI; Murphy S; Scott J; Garnett JP; Carrie S; Powell J; Khan CMA; Huang L; Hussain R; Coxhead J; Davey T; Simpson AJ; Haniffa M; Hambleton S; Brodlie M; Ward C; Trost M; Reynolds G; Duncan CJA
Nat Commun; 2021 Dec; 12(1):7092. PubMed ID: 34876592
[TBL] [Abstract][Full Text] [Related]
15. Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells.
Stanifer ML; Kee C; Cortese M; Zumaran CM; Triana S; Mukenhirn M; Kraeusslich HG; Alexandrov T; Bartenschlager R; Boulant S
Cell Rep; 2020 Jul; 32(1):107863. PubMed ID: 32610043
[TBL] [Abstract][Full Text] [Related]
16. Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 infection.
Chiale C; Greene TT; Zuniga EI
Immunol Rev; 2022 Aug; 309(1):12-24. PubMed ID: 35775361
[TBL] [Abstract][Full Text] [Related]
17. Importance of Type I and III Interferons at Respiratory and Intestinal Barrier Surfaces.
Stanifer ML; Guo C; Doldan P; Boulant S
Front Immunol; 2020; 11():608645. PubMed ID: 33362795
[TBL] [Abstract][Full Text] [Related]
18. [The problem of the use of interferons in the novel coronavirus disease COVID-19 (Coronaviridae: Coronavirinae: Betacoronavirus: Sarbecovirus)].
Ershov FI; Narovlyansky AN
Vopr Virusol; 2022 May; 67(2):115-125. PubMed ID: 35521984
[TBL] [Abstract][Full Text] [Related]
19. Herpesviruses and the Type III Interferon System.
Yin Y; Favoreel HW
Virol Sin; 2021 Aug; 36(4):577-587. PubMed ID: 33400088
[TBL] [Abstract][Full Text] [Related]
20. Interferon-lambda: New role in intestinal symptoms of COVID-19.
Pan YY; Wang LC; Yang F; Yu M
World J Gastroenterol; 2023 Apr; 29(13):1942-1954. PubMed ID: 37155525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
